Treatment of Lichen Planus
High-potency topical corticosteroids remain the first-line treatment for lichen planus across all variants, with topical calcineurin inhibitors (particularly tacrolimus 0.1%) serving as the primary alternative for refractory cases, while JAK inhibitors (tofacitinib, upadacitinib) represent the most promising emerging therapy for treatment-resistant disease.
First-Line Therapy: Topical Corticosteroids
Topical corticosteroids are the gold standard for initial management of lichen planus. For oral lichen planus specifically, topical corticosteroids demonstrate equivalent efficacy to calcineurin inhibitors but with a more favorable side effect profile 1, 2. The evidence shows that topical steroids slightly outperform calcineurin inhibitors in reducing pain at 4 weeks (though not statistically significant) and promote marginally better healing 2.
For cutaneous lichen planus: Apply high-potency topical corticosteroids (such as clobetasol propionate) directly to affected areas 3.
For oral lichen planus: Use topical corticosteroid preparations designed for oral mucosa application 1, 2.
For nail lichen planus: Clobetasol propionate is the topical agent of choice 3.
Second-Line Therapy: Topical Calcineurin Inhibitors
When topical corticosteroids fail or are contraindicated, topical calcineurin inhibitors become the treatment of choice. Tacrolimus 0.1% should be the first calcineurin inhibitor selected based on the most robust evidence 1.
The meta-analysis of 21 trials involving 965 patients demonstrated that tacrolimus, pimecrolimus, and ciclosporin show similar efficacy to topical corticosteroids for short-term treatment (3-8 weeks) 1. However, there is a critical caveat: tacrolimus causes statistically higher rates of local adverse events, particularly transient burning sensation during the first two days of treatment 1, 2. This burning occurs more than twice as often compared to steroids (OR: 2.45) 2.
Blood levels of topical calcineurin inhibitors are typically undetectable, minimizing systemic concerns 1.
Intralesional Therapy
For localized, resistant lesions, intralesional triamcinolone injections are effective, particularly for nail lichen planus and erosive oral lichen planus 3, 4.
Systemic Therapy for Moderate-to-Severe or Refractory Disease
Systemic Corticosteroids
For widespread or severe disease, systemic corticosteroids demonstrate the highest complete resolution rate among monotherapies at 88.9% (24 of 27 patients) 5. However, use should be limited due to well-known long-term adverse effects.
JAK Inhibitors: The Most Promising Emerging Therapy
JAK inhibitors represent a paradigm shift in treating refractory lichen planus, with mounting evidence supporting their use when conventional therapies fail.
Efficacy data:
- Tofacitinib: 75.0% complete resolution rate (6 of 8 patients) as monotherapy 5
- Upadacitinib: Demonstrated complete resolution of erosive oral lichen planus at 30 mg daily in a patient who failed multiple prior therapies including prednisone, clobetasol, mycophenolate, and biologics 4
- Overall JAK inhibitor class: Rapid reduction in pruritus and pain, followed by clinical resolution across diverse variants 6
The mechanistic rationale is compelling: JAK1 and JAK3 are overexpressed in lichen planus inflammatory infiltrates, and the Th1/IFN-γ cytokine pathway driving lichen planus inflammation is directly targeted by JAK-STAT pathway inhibition 4, 6.
A 2026 systematic review of 84 studies concluded that JAK inhibitors demonstrate promising preliminary clinical response with acceptable short-term safety for refractory lichen planus variants 6. Both systemic agents (tofacitinib, upadacitinib, baricitinib) and topical formulations (ruxolitinib) showed efficacy 6.
Biologics
Among biologic monotherapies, tildrakizumab (IL-23 inhibitor) achieved 88.0% complete resolution (22 of 25 patients) in vulvovaginal lichen planus 5. The overall complete resolution rate across all 31 biologic-treated patients was 71.0% 5. Notably, tildrakizumab showed a remarkably low recurrence rate of only 3.2% 5.
TNF-alpha inhibitors like etanercept have been reported for nail lichen planus 3.
Other Systemic Immunosuppressants
- Oral calcineurin inhibitors (cyclosporine)
- Mycophenolate mofetil
- Retinoids (acitretin)
- Antimalarials (hydroxychloroquine, chloroquine)
- Dapsone
These agents are used for refractory cases but have variable efficacy and significant side effect profiles 3, 7, 8.
Combination Therapy for Resistant Cases
Triple-component therapy is frequently employed for treatment-resistant lichen planus, particularly vulvovaginal disease. The most commonly used combination (66.8% of cases) consists of:
- Systemic corticosteroids
- Topical calcineurin inhibitors
- Antimetabolites (methotrexate or mycophenolate mofetil)
This combination achieved 41.6% complete resolution in resistant cases 5.
Treatment Algorithm by Variant
Oral Lichen Planus
- First-line: Topical corticosteroids
- Second-line: Tacrolimus 0.1% (if steroids fail or contraindicated)
- Refractory erosive disease: Intralesional triamcinolone or systemic therapy
- Severe refractory disease: JAK inhibitors (upadacitinib 15-30 mg daily) 4
Nail Lichen Planus
- First-line: Clobetasol propionate topically
- Second-line: Topical tacrolimus or intralesional triamcinolone
- Refractory: JAK inhibitors 3
Vulvovaginal Lichen Planus
- First-line: Intravaginal corticosteroid suppositories (55.7% complete resolution)
- Refractory: Triple-component therapy (systemic steroids + topical calcineurin inhibitor + antimetabolite)
- Severe refractory: Tildrakizumab or JAK inhibitors 5
Plantar Ulcerative Lichen Planus
This rare variant is particularly treatment-resistant. Options include topical/systemic corticosteroids, calcineurin inhibitors, retinoids, cyclosporine, dapsone, phototherapy, and JAK inhibitors, though outcomes are variable and no standardized approach exists 7.
Critical Pitfalls and Caveats
Recurrence rates vary dramatically by treatment:
- Topical corticosteroids alone: 84% recurrence
- Methotrexate: 11.9% recurrence
- Tildrakizumab: 3.2% recurrence 5
High recurrence rates with monotherapy suggest that combination approaches may be necessary for long-term disease control 5.
The transient burning sensation with calcineurin inhibitors occurs predominantly in the first 48 hours and should be anticipated and explained to patients to improve adherence 1, 2.
JAK inhibitor evidence is promising but limited: Current data relies heavily on case reports, case series, and small observational studies. The certainty of evidence is low, and large randomized controlled trials with long-term follow-up are needed 6. Short-term adverse effects have been mild and manageable in reported cases 6.
Lichen planus is a potentially malignant disorder, particularly oral variants, requiring long-term monitoring regardless of treatment response 2, 8.